Nicholas Hornstein, Gastrointestinal Medical Oncologist at Northwell Health Cancer Institute and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared on X:
“Interesting weekend surprise.
The FDA has rejected ivonescimab (PD-1 × VEGF) in EGFR-mutant NSCLC despite a significant PFS benefit (HR 0.52). The reason? No statistically significant OS benefit.
Not GI oncology, but VERY relevant to oncology drug development. Remember MARIPOSA? Amivantamab + lazertinib received FDA approval based on PFS, with OS as a secondary endpoint and immature survival data at approval.
Yes. I know. HARMONi had co-primary PFS/OS endpoints, while MARIPOSA had PFS as its primary endpoint. Not identical trials.
But here’s my question:
Who wants to bet that if ivonescimab had been developed entirely in the US, rather than licensed from China’s Akeso, we’d be looking at an approval today?
Maybe the FDA is simply holding sponsors to their prespecified endpoints. Fair enough. But are we applying a consistent evidentiary standard across oncology drugs?
Because that matters a LOT more than just this one approval.
About the FDA Decision on Ivonescimab and the HARMONi Trial
On November 15, 2026, Summit Therapeutics announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) for ivonescimab in combination with platinum-based chemotherapy for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with EGFR tyrosine kinase inhibitors.
The application was supported by the global Phase III HARMONi trial, which evaluated ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy.
The trial demonstrated a statistically significant improvement in progression-free survival (PFS), with median PFS of 6.8 months versus 4.4 months for chemotherapy alone (HR 0.52). However, the primary overall survival analysis showed 16.8 versus 14.0 months (HR 0.79; P = .057), failing to reach statistical significance.
